ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
22.33 USD
+0.48 (+2.2%)
23.3 USD
+0.97 (+4.34%)
ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, ACAD could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
In the past 5 years ACAD reported 4 times negative net income.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
1.2 Ratios
ACAD has a better Return On Assets (18.13%) than 96.44% of its industry peers.
ACAD's Return On Equity of 27.01% is amongst the best of the industry. ACAD outperforms 97.19% of its industry peers.
ACAD has a Return On Invested Capital of 8.85%. This is amongst the best in the industry. ACAD outperforms 94.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROIC | 8.85% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD has a better Profit Margin (21.80%) than 94.94% of its industry peers.
ACAD has a better Operating Margin (8.86%) than 91.76% of its industry peers.
ACAD's Gross Margin of 91.97% is amongst the best of the industry. ACAD outperforms 92.51% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ACAD is creating some value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.71 indicates that ACAD is not in any danger for bankruptcy at the moment.
ACAD's Altman-Z score of 4.71 is fine compared to the rest of the industry. ACAD outperforms 74.34% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.71 |
ROIC/WACC1.01
WACC8.74%
2.3 Liquidity
A Current Ratio of 2.91 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a Current ratio of 2.91. This is in the lower half of the industry: ACAD underperforms 64.79% of its industry peers.
A Quick Ratio of 2.83 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a worse Quick ratio (2.83) than 64.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 150.00%, which is quite impressive.
ACAD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.41%.
ACAD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.08% yearly.
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
3.2 Future
Based on estimates for the next years, ACAD will show a very strong growth in Earnings Per Share. The EPS will grow by 41.41% on average per year.
The Revenue is expected to grow by 10.77% on average over the next years. This is quite good.
EPS Next Y23.29%
EPS Next 2Y36.43%
EPS Next 3Y36.92%
EPS Next 5Y41.41%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y10.64%
Revenue Next 5Y10.77%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.62 indicates a quite expensive valuation of ACAD.
92.13% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
ACAD is valuated expensively when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 24.99 indicates a rather expensive valuation of ACAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.76% of the companies listed in the same industry.
ACAD's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.62 | ||
| Fwd PE | 24.99 |
4.2 Price Multiples
93.07% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 92.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.65 | ||
| EV/EBITDA | 23.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 36.92% in the coming years.
PEG (NY)2.13
PEG (5Y)N/A
EPS Next 2Y36.43%
EPS Next 3Y36.92%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.33
+0.48 (+2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change-0.19%
Ins Owners0.3%
Ins Owner Change1.1%
Market Cap3.77B
Revenue(TTM)1.02B
Net Income(TTM)222.16M
Analysts76.15
Price Target29.74 (33.18%)
Short Float %5.22%
Short Ratio4.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)-3.17%
PT rev (3m)2.71%
EPS NQ rev (1m)-2.1%
EPS NQ rev (3m)7.25%
EPS NY rev (1m)3.26%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.62 | ||
| Fwd PE | 24.99 | ||
| P/S | 3.7 | ||
| P/FCF | 42.65 | ||
| P/OCF | 20.04 | ||
| P/B | 4.58 | ||
| P/tB | 5.32 | ||
| EV/EBITDA | 23.24 |
EPS(TTM)0.45
EY2.02%
EPS(NY)0.89
Fwd EY4%
FCF(TTM)0.52
FCFY2.34%
OCF(TTM)1.11
OCFY4.99%
SpS6.04
BVpS4.87
TBVpS4.2
PEG (NY)2.13
PEG (5Y)N/A
Graham Number7.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROCE | 10.08% | ||
| ROIC | 8.85% | ||
| ROICexc | 59.33% | ||
| ROICexgc | 412.73% | ||
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% | ||
| FCFM | 8.67% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 9.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 180.83% | ||
| Profit Quality | 39.76% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 4.71 |
F-Score6
WACC8.74%
ROIC/WACC1.01
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y23.29%
EPS Next 2Y36.43%
EPS Next 3Y36.92%
EPS Next 5Y41.41%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
Revenue Next Year9.96%
Revenue Next 2Y10.97%
Revenue Next 3Y10.64%
Revenue Next 5Y10.77%
EBIT growth 1Y307.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 23.29% in the next year.